Completed OBSERVATIONAL NCT03015168

Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients

Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients Who Received Capecitabine and Concurrent Intensity Modulated Radiotherapy (IMRT)

Sponsor: General Hospital of Ningxia Medical University

Conditions Prognosis Rectal Cancer

Interventions capecitabine and concurrent intensity modulated radiotherapy

Updated 5 times since 2017 Last updated: Jan 6, 2017 Started: Jan 31, 2012 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Prognosis and Rectal Cancer and is currently completed. General Hospital of Ningxia Medical University leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

General Hospital of Ningxia Medical University

Data source: General Hospital of Ningxia Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yinchuan, China